Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542322 | 0.95 | TP53 (0.52) | TP53MAPTPARP1MMP9HPGD | |
| SCHEMBL23542306 | 0.90 | TP53 (0.55) | TP53MAPTPARP1MMP9HPGD | |
| SCHEMBL23542305 | 0.87 | MAPT (0.50) | TP53MAPTMMP9HPGDMEN1 | |
| SCHEMBL23542320 | 0.84 | MMP9 (0.55) | TP53MAPTPARP1MMP9HPGD | |
| SCHEMBL23542324 | 0.82 | MMP9 (0.49) | TP53MAPTMMP9HPGDMEN1 | |
| SCHEMBL23542301 | 0.82 | MMP9 (0.64) | TP53MAPTMMP9HPGDALDH1A1 | |
| SCHEMBL23542296 | 0.81 | MMP13 (0.54) | TP53MAPTPARP1MMP9HPGD | |
| SCHEMBL23542308 | 0.79 | MMP9 (0.69) | TP53MAPTMMP9HPGDMEN1 | |
| SCHEMBL23542298 | 0.77 | MAPT (0.61) | TP53MAPTPARP1MMP9HPGD | |
| SCHEMBL23542316 | 0.75 | MMP9 (0.48) | TP53MAPTMMP9HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-07 | — | — | US | disclosed |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP9, MMP7, MMP11 | TP53 864/4885MAPT 422/4885PARP1 416/4885 |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | MMP2, MMP9, MMP10 | TP53 903/4885MAPT 4268/4885PARP1 708/4885 |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP2, CBR3, NR4A3 | TP53 4643/4885MAPT 4861/4885PARP1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.